These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30392291)

  • 21. Role of the hypocretin (orexin) receptor 2 (Hcrt-r2) in the regulation of hypocretin level and cataplexy.
    Wu MF; Nienhuis R; Maidment N; Lam HA; Siegel JM
    J Neurosci; 2011 Apr; 31(17):6305-10. PubMed ID: 21525270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy.
    Baier PC; Hallschmid M; Seeck-Hirschner M; Weinhold SL; Burkert S; Diessner N; Göder R; Aldenhoff JB; Hinze-Selch D
    Sleep Med; 2011 Dec; 12(10):941-6. PubMed ID: 22036605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls.
    Nishino S; Sakurai E; Nevsimalova S; Yoshida Y; Watanabe T; Yanai K; Mignot E
    Sleep; 2009 Feb; 32(2):175-80. PubMed ID: 19238804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Traditional biomarkers in narcolepsy: experience of a Brazilian sleep centre.
    Coelho FM; Pradella-Hallinan M; Pedrazzoli M; Soares CA; Fernandes GB; Gonçalves AL; Tufik S; Bittencourt LR
    Arq Neuropsiquiatr; 2010 Oct; 68(5):712-5. PubMed ID: 21049180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia.
    Kanbayashi T; Inoue Y; Chiba S; Aizawa R; Saito Y; Tsukamoto H; Fujii Y; Nishino S; Shimizu T
    J Sleep Res; 2002 Mar; 11(1):91-3. PubMed ID: 11869432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.
    Black SW; Morairty SR; Fisher SP; Chen TM; Warrier DR; Kilduff TS
    Sleep; 2013 Mar; 36(3):325-36. PubMed ID: 23449602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ventilatory chemoresponsiveness, narcolepsy-cataplexy and human leukocyte antigen DQB1*0602 status.
    Han F; Mignot E; Wei YC; Dong SX; Li J; Lin L; An P; Wang LH; Wang JS; He MZ; Gao HY; Li M; Gao ZC; Strohl KP
    Eur Respir J; 2010 Sep; 36(3):577-83. PubMed ID: 20110394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1.
    van der Hoeven AE; Fronczek R; Schinkelshoek MS; Roelandse FWC; Bakker JA; Overeem S; Bijlenga D; Lammers GJ
    Sleep; 2022 May; 45(5):. PubMed ID: 35554594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of measuring CSF hypocretin-1 level in patients with suspected narcolepsy.
    Gabryelska A; Szmyd B; Maschauer EL; Roguski A; Canham R; Morrison I; Białasiewicz P; Riha RL
    Sleep Med; 2020 Jul; 71():48-51. PubMed ID: 32492554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy.
    Thannickal TC; Nienhuis R; Siegel JM
    Sleep; 2009 Aug; 32(8):993-8. PubMed ID: 19725250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developmental changes in CSF hypocretin-1 (orexin-A) levels in normal and genetically narcoleptic Doberman pinschers.
    John J; Wu MF; Maidment NT; Lam HA; Boehmer LN; Patton M; Siegel JM
    J Physiol; 2004 Oct; 560(Pt 2):587-92. PubMed ID: 15308685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HLA and hypocretin studies in Korean patients with narcolepsy.
    Hong SC; Leen-Kim ; Park SA; Han JH; Lee SP; Lin L; Okun M; Nishino S; Mignot E
    Sleep; 2002 Jun; 25(4):440-4. PubMed ID: 12071546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypocretin deficiency develops during onset of human narcolepsy with cataplexy.
    Savvidou A; Knudsen S; Olsson-Engman M; Gammeltoft S; Jennum P; Palm L
    Sleep; 2013 Jan; 36(1):147-8. PubMed ID: 23288981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Narcolepsy in African Americans.
    Kawai M; O'Hara R; Einen M; Lin L; Mignot E
    Sleep; 2015 Nov; 38(11):1673-81. PubMed ID: 26158891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy.
    Nishino S; Ripley B; Overeem S; Nevsimalova S; Lammers GJ; Vankova J; Okun M; Rogers W; Brooks S; Mignot E
    Ann Neurol; 2001 Sep; 50(3):381-8. PubMed ID: 11558795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased cerebrospinal fluid levels of nerve cell biomarkers in narcolepsy with cataplexy.
    Heier MS; Skinningsrud A; Paus E; Gautvik KM
    Sleep Med; 2014 Jun; 15(6):614-8. PubMed ID: 24784789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients.
    Mignot E; Hayduk R; Black J; Grumet FC; Guilleminault C
    Sleep; 1997 Nov; 20(11):1012-20. PubMed ID: 9456467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated glial fibrillary acidic protein levels in the cerebrospinal fluid of patients with narcolepsy.
    Feneberg E; Steinacker P; Lehnert S; Böhm B; Mayer G; Otto M
    Sleep Med; 2013 Jul; 14(7):692-4. PubMed ID: 23746601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of hypocretin/orexin cell transplantation on narcoleptic-like sleep behavior in rats.
    Arias-Carrión O; Murillo-Rodríguez E
    PLoS One; 2014; 9(4):e95342. PubMed ID: 24736646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid hypocretin 1 deficiency, overweight, and metabolic dysregulation in patients with narcolepsy.
    Heier MS; Jansson TS; Gautvik KM
    J Clin Sleep Med; 2011 Dec; 7(6):653-8. PubMed ID: 22171205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.